^
Association details:
| Biomarker: | SMARCA4 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | MRTX2219 (PRC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MRTX2219 is an imidazopyrimidine binder to EED that inhibits polycomb repressive complex 2 (PRC2) and demonstrates robust in vivo activity in EZH2 and SMARCB1-mutant, but not other SWI/SNF-mutant cancer models
Published date:
05/15/2020
Excerpt:
While a PRC2 inhibitor may be active in molecularly-defined subsets of SWI/SNF or KDM6A-mutant cancers, overall these data suggest this approach is unlikely to be broadly effective as a single agent in SWI/SNF or KDM6A-mutant cancers. In summary, MRTX2219 is a potent and orally bioactive EED inhibitor that represents a differentiated strategy to block PRC2 activity in selected cancers.
